JPWO2022133239A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022133239A5 JPWO2022133239A5 JP2023536859A JP2023536859A JPWO2022133239A5 JP WO2022133239 A5 JPWO2022133239 A5 JP WO2022133239A5 JP 2023536859 A JP2023536859 A JP 2023536859A JP 2023536859 A JP2023536859 A JP 2023536859A JP WO2022133239 A5 JPWO2022133239 A5 JP WO2022133239A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- immunoglobulin protein
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 80
- 108060003951 Immunoglobulin Proteins 0.000 claims 67
- 102000018358 immunoglobulin Human genes 0.000 claims 67
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 34
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 34
- 239000003795 chemical substances by application Substances 0.000 claims 33
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 claims 27
- 108010038640 atrial natriuretic factor receptor A Proteins 0.000 claims 27
- 239000003814 drug Substances 0.000 claims 25
- 229940079593 drug Drugs 0.000 claims 25
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 21
- 239000012634 fragment Substances 0.000 claims 20
- 239000000556 agonist Substances 0.000 claims 19
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 238000012986 modification Methods 0.000 claims 12
- 230000004048 modification Effects 0.000 claims 12
- 102000040430 polynucleotide Human genes 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 12
- 239000002157 polynucleotide Substances 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 230000000004 hemodynamic effect Effects 0.000 claims 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 229940124572 antihypotensive agent Drugs 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000005526 vasoconstrictor agent Substances 0.000 claims 2
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical group COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010004977 Vasopressins Proteins 0.000 claims 1
- 102000002852 Vasopressins Human genes 0.000 claims 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 229960001094 midodrine Drugs 0.000 claims 1
- 230000029865 regulation of blood pressure Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127959P | 2020-12-18 | 2020-12-18 | |
| US63/127,959 | 2020-12-18 | ||
| PCT/US2021/064073 WO2022133239A1 (en) | 2020-12-18 | 2021-12-17 | Immunoglobulin proteins that bind to npr1 agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024503784A JP2024503784A (ja) | 2024-01-29 |
| JPWO2022133239A5 true JPWO2022133239A5 (https=) | 2024-12-24 |
| JP2024503784A5 JP2024503784A5 (https=) | 2024-12-24 |
Family
ID=79687048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536859A Pending JP2024503784A (ja) | 2020-12-18 | 2021-12-17 | Ｎｐｒ１アゴニストに結合する免疫グロブリンタンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12325752B2 (https=) |
| EP (1) | EP4263616A1 (https=) |
| JP (1) | JP2024503784A (https=) |
| KR (1) | KR20230132468A (https=) |
| CN (1) | CN116964101A (https=) |
| AU (1) | AU2021401415A1 (https=) |
| CA (1) | CA3202629A1 (https=) |
| CL (1) | CL2023001680A1 (https=) |
| CO (1) | CO2023009498A2 (https=) |
| IL (1) | IL303542A (https=) |
| MX (1) | MX2023007023A (https=) |
| WO (1) | WO2022133239A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY205168A (en) | 2018-10-23 | 2024-10-04 | Regeneron Pharma | Anti-npr1 antibodies and uses thereof |
| US12325752B2 (en) | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
| IL311917A (en) * | 2021-10-11 | 2024-06-01 | Regeneron Pharma | Methods for Inducing Hemodynamic Change by Administering an Anti-NPR1 Antibody |
| IL313265A (en) | 2021-12-06 | 2024-08-01 | Regeneron Pharma | Antagonistic antibodies against NPR1 and methods of using them |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2004011618A2 (en) | 2002-07-29 | 2004-02-05 | Hmgene, Inc. | Methods of identifying adipocyte specific genes, the genes identified, and their uses |
| US20080214437A1 (en) | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| EP2162464A1 (en) | 2007-06-06 | 2010-03-17 | Boehringer Ingelheim International GmbH | Natriuretic fusion proteins |
| US9090695B2 (en) | 2008-12-03 | 2015-07-28 | Morphosys Ag | Antibodies for guanylyl cyclase receptors |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
| US9451770B2 (en) | 2012-06-08 | 2016-09-27 | Charles Despres | Method of activating immune response in plants |
| LT3495387T (lt) * | 2012-07-13 | 2021-11-25 | Roche Glycart Ag | Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| RU2646098C2 (ru) * | 2013-04-30 | 2018-03-01 | Интас Фармасьютикалс Лтд | Новый способ клонирования, экспрессии и очистки для получения ранибизумаба |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| WO2016131943A1 (en) | 2015-02-20 | 2016-08-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes |
| WO2017209553A2 (ko) | 2016-06-03 | 2017-12-07 | 사회복지법인 삼성생명공익재단 | 환자 유래 세포를 이용한 항체 스크리닝 방법 |
| US20190248888A1 (en) | 2016-10-20 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| KR20200041834A (ko) * | 2017-06-01 | 2020-04-22 | 젠코어 인코포레이티드 | Cd123 및 cd3에 결합하는 이중특이성 항체 |
| US20190135804A1 (en) | 2017-11-03 | 2019-05-09 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Compositions and methods for the inhibition of pruritus |
| MY205168A (en) | 2018-10-23 | 2024-10-04 | Regeneron Pharma | Anti-npr1 antibodies and uses thereof |
| EP3898700A1 (en) | 2018-12-18 | 2021-10-27 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| EA202193345A1 (ru) | 2019-06-12 | 2022-03-16 | Новартис Аг | Антитела к рецептору-1 натрийуретического пептида и способы их применения |
| EP4259661A1 (en) | 2020-12-14 | 2023-10-18 | Novartis AG | Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof |
| US12325752B2 (en) | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
| IL313265A (en) | 2021-12-06 | 2024-08-01 | Regeneron Pharma | Antagonistic antibodies against NPR1 and methods of using them |
-
2021
- 2021-12-17 US US17/554,276 patent/US12325752B2/en active Active
- 2021-12-17 IL IL303542A patent/IL303542A/en unknown
- 2021-12-17 CN CN202180093936.1A patent/CN116964101A/zh active Pending
- 2021-12-17 AU AU2021401415A patent/AU2021401415A1/en active Pending
- 2021-12-17 EP EP21844504.7A patent/EP4263616A1/en active Pending
- 2021-12-17 CA CA3202629A patent/CA3202629A1/en active Pending
- 2021-12-17 KR KR1020237024056A patent/KR20230132468A/ko active Pending
- 2021-12-17 MX MX2023007023A patent/MX2023007023A/es unknown
- 2021-12-17 JP JP2023536859A patent/JP2024503784A/ja active Pending
- 2021-12-17 WO PCT/US2021/064073 patent/WO2022133239A1/en not_active Ceased
-
2023
- 2023-06-09 CL CL2023001680A patent/CL2023001680A1/es unknown
- 2023-07-17 CO CONC2023/0009498A patent/CO2023009498A2/es unknown
-
2025
- 2025-05-13 US US19/206,976 patent/US20250333524A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7375122B2 (ja) | ヒト化、マウスまたはキメラ抗ｃｄ４７モノクローナル抗体 | |
| JP7143452B2 (ja) | ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用 | |
| JP2021508469A5 (https=) | ||
| CN111417653A (zh) | Cd47抗原结合分子 | |
| US20220356235A1 (en) | Factor h potentiating antibodies and uses thereof | |
| JPWO2019129221A5 (https=) | ||
| JP2021520825A5 (https=) | ||
| WO2022105914A1 (zh) | Cd70抗体及其应用 | |
| CA3097193A1 (en) | Anti-dll3 antibodies and uses thereof | |
| JP2021511387A5 (https=) | ||
| JP7717687B2 (ja) | 腎疾患における抗幹細胞因子抗体及びその使用方法 | |
| EP4165082A1 (en) | Antibodies binding tnfr2 and uses thereof | |
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| TWI834254B (zh) | α-烯醇酶拮抗劑治療纖維化疾病之用途 | |
| JPWO2022133239A5 (https=) | ||
| JP2021521201A5 (https=) | ||
| JPWO2022268192A5 (https=) | ||
| JPWO2020086406A5 (https=) | ||
| JPWO2021042019A5 (https=) | ||
| JPWO2021202590A5 (https=) | ||
| JPWO2020264384A5 (https=) | ||
| JPWO2019140216A5 (https=) | ||
| JPWO2021163170A5 (https=) | ||
| TWI825687B (zh) | 抗ｃｘｃｒ２抗體及其用途 | |
| JP2021526833A5 (https=) |